Primo Biotechnology Co., Ltd. announced that its Taoyuan pharmaceutical facility has received dual certification for PIC/S GMP and GDP from the Taiwan Food and Drug Administration (TFDA). This certification highlights the company's commitment to international quality standards in nuclear medicine production and supports its global market growth. Since construction began in 2023, Primo has integrated advanced production systems, achieving certification in under two years. Additionally, the company received market approval for its critical radiopharmaceutical, Fluorodeoxyglucose F-18 (18F-FDG), which is essential for PET/CT imaging in cancer and other conditions. Primo is also expanding into Clinical Research Organization and Contract Development and Manufacturing Organization services, enhancing its drug development and manufacturing capabilities. With a strategic location near Taoyuan International Airport, the company aims for secure and efficient delivery of its products globally.
Thu, 24 Apr 2025 15:00:00 GMT | PR Newswire